Omega Diagnostics (ODX) is still very much in its early development phase, which was reflected in unremarkable half-year results. Revenue for the period increased marginally to £5.59m from £5.53m last time, while profits edged ahead by 25 per cent from a low base to £164, 480.
Much of Omega's success will depend on how well its point-of-care test for CD4 T-helper cells in HIV patients is received by medical authorities. So far, it has decided on a manufacturing protocol for the test and it will now go to external evaluation before it is ready for regulatory scrutiny and eventual marketing. It is also in the final stages of finalising new tests for Immunodiagnostic Systems' IDS-iSYS machine, although the development timetable appears to be behind schedule.
